RVPH (Reviva Pharmaceuticals Holdings) Net Margin %: 0.00% (As of Mar. 2026)


RVPH Reviva Pharmaceuticals Holdings Inc RVPH
22 GF Score
Price $0.61
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Net Margin %?

Reviva Pharmaceuticals Holdings RVPH +1.68% 22 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates RVPH with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Reviva Pharmaceuticals Holdings ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Reviva Pharmaceuticals Holdings's Net Income for the three months ended in Mar. 2026 was $-3.20 Mil. Reviva Pharmaceuticals Holdings's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Reviva Pharmaceuticals Holdings's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Net Margin % or its related term are showing as below:


RVPH's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Reviva Pharmaceuticals Holdings  (OTCPK:RVPH) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Reviva Pharmaceuticals Holdings Net Margin % Related Terms

Reviva Pharmaceuticals Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Reviva Pharmaceuticals Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reviva Pharmaceuticals Holdings Net Margin % Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Reviva Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RVPH vs MLEC, DRMA, MTNB: Net Margin % Comparison

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Net Margin % falls into.


RVPH
22GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Reviva Pharmaceuticals Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Reviva Pharmaceuticals Holdings's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-19.865/0
= %

Reviva Pharmaceuticals Holdings's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.196/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Reviva Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #999999 out of 946 companies in the Biotechnology industry.
Is Reviva Pharmaceuticals Holdings' Net Margin % too high?
Reviva Pharmaceuticals Holdings' current Net Margin % is 0.00%. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Net Margin % compare to MLEC and DRMA?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #999999 out of 946 companies for Net Margin %. This places Reviva Pharmaceuticals Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score

Get the complete analysis for RVPH

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price